1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON...

1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM)

Hauschild, A., Grobb, J., Demidov, L., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C., Miller, W., Martin-Algarra, S., Karaszewska, B., Mauch, C., Chiarion Sileni, V., Aktan, G., Hane
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
25
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdu344.8
Date:
September, 2014
File:
PDF, 70 KB
2014
Conversion to is in progress
Conversion to is failed